Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.

ABSTRACT:

Background

Ovarian cancer has the highest mortality rate of all gynecologic malignancy. The receptor tyrosine kinases (RTKs), including EGFR, ERBB2, PDGFR, VEGFR and MET, are activated in subsets of ovarian cancer, suggesting that these kinases might represent novel therapeutic targets. However, clinical trials have not or just partially shown benefit to ovarian cancers treated with EGFR, ERBB2, or PDGFR inhibitors. Despite multiple RTK activation in ovarian cancer pathogenesis, it is unclear whether transforming activity is dependent on an individual kinase oncoprotein or the coordinated activity of multiple kinases. We hypothesized that a coordinated network of multi-RTK activation is important for the tumorigenesis of ovarian cancers.

Results

Herein, we demonstrate co-act

SUBMITTER: Jiao Y 

PROVIDER: S-EPMC3196924 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature